Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 + Chemotherapy in Early Triple-Negative Breast Cancer
NCT07372079Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Apr 2026
- Primary completion
- Dec 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in triple negative breast cancer (TNBC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Apr 2026; status: recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07372079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07372079.